DMD

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on December 17, 2004; DOI: 10.1124/dmd.104.002097


0090-9556/05/3303-466-473$20.00
DMD 33:466-473, 2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.104.002097v1
33/3/466    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Delaforge, M.
Right arrow Articles by André, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Delaforge, M.
Right arrow Articles by André, F.

CYTOCHROME P450-MEDIATED OXIDATION OF GLUCURONIDE DERIVATIVES: EXAMPLE OF ESTRADIOL-17ß-GLUCURONIDE OXIDATION TO 2-HYDROXY-ESTRADIOL-17ß-GLUCURONIDE BY CYP 2C8

M. Delaforge, A. Pruvost, L. Perrin, and F. André

Service de Pharmacologie et d'Immunologie, Direction des Sciences du Vivant/Département de Recherche Médicale (M.D., A.P.); and Centre National de la Recherche Scientifique, Unité de Recherche Associée 2096, Département de Biologie Joliot Curie (M.D., L.P., F.A.), Commissariat à l'Energie Atomique, Saclay, France

In the classical metabolic oxidation scheme, hydrophobic endogenous or xenobiotic compounds undergo phase I oxidation, generally catalyzed in the liver by cytochromes P450, followed by phase II conjugation reactions, in a way that allows much more polar metabolites to be expelled from the cell through active transport mechanisms. Cytochrome P450-mediated oxidation of steroid sulfate has been described, suggesting that oxidation of polar metabolites such as glucuronide derivatives of endogenous compounds can occur. As an example, we report here that hydroxyestradiol-17ß-glucuronide can be directly formed through oxidation of estradiol-17ß-glucuronide on the aromatic C2 position. This reaction is specifically catalyzed by CYP 2C8, which is more active in female than in male human liver microsomes. A thorough docking of the molecule within the CYP 2C8 crystal structure shows that the active site is large enough to handle a glucuronide conjugate. Moreover, the most energetically favored position of the bound ligand is fully consistent with the recently published structural determinants of substrate specificity of the CYP 2C8 active site. This is the first demonstration of cytochrome P450-mediated oxidation of a steroid glucuro-conjugate. Such oxidation of a glucuronide should be a general process since, in addition to estradiol and testosterone glucuronide, it has been observed for xenobiotic compounds, e.g., diclofenac or naproxen glucuronide.


Address correspondence to: M. Delaforge, CEA Saclay, CNRS URA 2096 DSV/DBJC Bat532, 91191 Gif-sur-Yvette cedex, France. E-mail: marcel.delaforge{at}cea.fr




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
G. A. Schoch, J. K. Yano, S. Sansen, P. M. Dansette, C. D. Stout, and E. F. Johnson
Determinants of Cytochrome P450 2C8 Substrate Binding: STRUCTURES OF COMPLEXES WITH MONTELUKAST, TROGLITAZONE, FELODIPINE, AND 9-CIS-RETINOIC ACID
J. Biol. Chem., June 20, 2008; 283(25): 17227 - 17237.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
W. Albrecht, A. Unger, A. K. Nussler, and S. Laufer
In Vitro Metabolism of 2-[6-(4-Chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl] Acetic Acid (Licofelone, ML3000), an Inhibitor of Cyclooxygenase-1 and -2 and 5-Lipoxygenase
Drug Metab. Dispos., May 1, 2008; 36(5): 894 - 903.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
L. Wang, D. Zhang, A. Swaminathan, Y. Xue, P. T. Cheng, S. Wu, R. Mosqueda-Garcia, C. Aurang, D. W. Everett, and W. G. Humphreys
GLUCURONIDATION AS A MAJOR METABOLIC CLEARANCE PATHWAY OF 14C-LABELED MURAGLITAZAR IN HUMANS: METABOLIC PROFILES IN SUBJECTS WITH OR WITHOUT BILE COLLECTION
Drug Metab. Dispos., March 1, 2006; 34(3): 427 - 439.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
B. W. Ogilvie, D. Zhang, W. Li, A. D. Rodrigues, A. E. Gipson, J. Holsapple, P. Toren, and A. Parkinson
GLUCURONIDATION CONVERTS GEMFIBROZIL TO A POTENT, METABOLISM-DEPENDENT INHIBITOR OF CYP2C8: IMPLICATIONS FOR DRUG-DRUG INTERACTIONS
Drug Metab. Dispos., January 1, 2006; 34(1): 191 - 197.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics.